Commission loss of ₹300 crore alleged in Delhi drug purchase

New Delhi – The Aam Aadmi Party’s Delhi chief, Saurabh Bhardwaj, has alleged that the Delhi government’s recent drug purchase scheme resulted in a commission loss estimated at ₹300 crore. The allegation stems from a claim that the state bought medicines worth ₹100 crore at an inflated cost of ₹400 crore, creating a massive financial discrepancy.

Bhardwaj asserted that the procurement paperwork shows a huge margin that cannot be justified by market rates. He said the inflated pricing points to a deliberate scheme to siphon public funds through intermediaries, with the excess amount likely being pocketed as illegal commissions.

Further, the party leader warned that the surplus funds may have facilitated the diversion of medicines to the private market. According to Bhardwaj, about 70‑80% of the procured stock could have been sold to chemists, while a meagre 20‑30% actually reached the government hospitals, leaving patients without essential treatment.

The accusations also reference the Sarvodaya Vallabhbhai Patel Hospital, where records indicate large drug orders, yet on‑site verification found the supplies missing. Bhardwaj highlighted the contrast between documented procurements and the actual availability of medicines, labeling the scenario a “multilevel corruption” episode.

The AAP demands immediate scrutiny of the tendering process, the missing work orders, and the disappearance of files related to the contracts. The party insists that a transparent inquiry is essential to restore public confidence and safeguard the health of Delhi’s residents.